ReviewBiological psychiatry2015
Imaging biomarkers associated with cognitive decline: a review.
Review in Biological psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Article
- Advancing diagnostic biomarkers in Alzheimer's disease: interdisciplinary innovations and technological frontiers.Human cell · 2026Review
- Explainable machine learning with bayesian hyper-optimization for predicting cognitive impairment from longitudinal nursing home data.Scientific reports · 2026Article
- Article
- Multimodal deep learning for dementia classification using text and audio.Scientific reports · 2024Article
- Associations between recall of proper names in story recall and CSF amyloid and tau in adults without cognitive impairment.Neurobiology of aging · 2024Article
- Gray and White Matter Voxel-Based Morphometry of Alzheimer's Disease With and Without Significant Cerebrovascular Pathologies.Neuroscience insights · 2024Article
- Hypermetabolic Cerebellar Connectome in Alzheimer's Disease.Brain connectivity · 2023Article
- Hippocampal atrophy is associated with hearing loss in cognitively normal adults.Frontiers in neuroscience · 2023Article
- Classification and prediction of cognitive performance differences in older age based on brain network patterns using a machine learning approach.Network neuroscience (Cambridge, Mass.) · 2023Article
- Developments in scalable strategies for detecting early markers of cognitive decline.Translational psychiatry · 2022Review
- The Future of Biomarkers in Veterinary Medicine: Emerging Approaches and Associated Challenges.Animals : an open access journal from MDPI · 2022Review
- Association Between Retinal Layer Thickness and Cognitive Decline in Older Adults.JAMA ophthalmology · 2022Article
- Diagnosis of early mild cognitive impairment using a multiobjective optimization algorithm based on T1-MRI data.Scientific reports · 2022Article
- Hippocampal glucose uptake as a surrogate of metabolic change of microglia in Alzheimer's disease.Journal of neuroinflammation · 2021Article
- Elevated caudate connectivity in cognitively normal Parkinson's disease patients.Scientific reports · 2020Article
- Combat exposure, posttraumatic stress disorder, and head injuries differentially relate to alterations in cortical thickness in military Veterans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Targeting age-related differences in brain and cognition with multimodal imaging and connectome topography profiling.Human brain mapping · 2019Article
- Brain biomarkers and cognition across adulthood.Human brain mapping · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In evaluating disease changes, it is critical to have measurements that are sensitive, specific, and reliable. Cognitive decline, particularly in the context of Alzheimer's disease, is an area that has attracted numerous recent studies, and the proposed biomarkers used in these investigations need to be validated. In this review, we highlight studies with important implications about the role of imaging biomarkers in cognitive decline and dementia as well as in distinguishing preclinical dementia before evidence of cognitive decline. Structural changes determined on cross-sectional and longitudinal magnetic resonance imaging provide early prediction of dementia, particularly when combined with other measures. Molecular imaging using positron emission tomography and single photon emission computed tomography tracers quantify the presence or activity of receptors, transporters, enzymes, metabolic pathways, and proteins. The newest developments in molecular imaging are described, and methods are compared. Distinguishing features of imaging biomarkers among dementias and the spectrum of preclinical Alzheimer's disease, mild cognitive impairment, and Alzheimer's disease are described. Appropriate use criteria for positron emission tomography with amyloid tracers are delineated. Although these efforts are still in the early phase of development, there is great promise for further development in structural magnetic resonance imaging and positron emission tomography technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.